Shares of Extendicare Inc. (TSE:EXE – Get Free Report) hit a new 52-week high during trading on Thursday . The stock traded as high as C$29.47 and last traded at C$29.47, with a volume of 88760 shares trading hands. The stock had previously closed at C$28.81.
Wall Street Analyst Weigh In
Several analysts have recently commented on EXE shares. Canadian Imperial Bank of Commerce raised their price objective on shares of Extendicare from C$22.00 to C$32.00 in a research report on Thursday, April 2nd. TD Securities upgraded shares of Extendicare from a “hold” rating to a “buy” rating and lifted their price target for the company from C$19.00 to C$32.00 in a report on Monday. National Bank Financial lifted their price target on shares of Extendicare from C$24.50 to C$29.00 and gave the company an “outperform” rating in a report on Thursday, February 5th. Finally, BMO Capital Markets lifted their price target on shares of Extendicare from C$24.00 to C$30.00 in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of C$28.64.
View Our Latest Analysis on Extendicare
Extendicare Stock Performance
Extendicare (TSE:EXE – Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported C$0.29 earnings per share (EPS) for the quarter. The company had revenue of C$462.03 million during the quarter. Extendicare had a net margin of 5.82% and a return on equity of 47.65%. On average, research analysts predict that Extendicare Inc. will post 0.6134729 earnings per share for the current year.
About Extendicare
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
See Also
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
